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A BSTR A C T
Currently, the most commonly used treatm ents for cancerous tum ors (chem other
apy, radiation, etc.) have almost no m ethod of monitoring the adm inistration of the
treatm ent for adverse effects in real time. W ithout any real tim e feedback or control,
treatm ent becomes a “guess and check” m ethod with no way of predicting the effects
of the drugs based on th e actual bioavailability to the p atien t’s body. One particular
drug may be effective for one patient, yet provide no benefit to another. Doctors and
scientists do not routinely attem p t to quantifiably explain this discrepancy.
In this work, m athem atical modeling and analysis techniques are joined to
gether with experim entation to gain further insight into the challenges of nanoparticle
uptake and retention in the bloodstream . Several models are presented here which
predict both the uptake and retention phases of the experim ent. There does exist
a commonly accepted model of drug clearance in the pharm acokinetics community,
and it is dem onstrated here th a t this model provides an accurate reflection of reality,
as observed in experiments, for delivery of gold-coated nanorods. This model is then
utilized in a state space feedback control framework to regulate th e nanoparticle con
centration in the bloodstream. An equal tim e delay is also introduced in both the
state and control input for the purpose of studying alternate dosing strategies. This
study will aid in the prediction of the effects of the drugs in a p a tie n t’s body, thus
leading to b etter models for drug regimen and adm inistration.
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C H A PT E R 1
IN TR O D U C TIO N
Though cancer therapies can be effective, there is almost no way to predict
the effect th a t a particular therapy will have on any one individual [34]. As current
treatm ent dosages are largely determ ined by the weight of the subject, there is
almost no way of predicting the efficacy or any adverse effects while th e drug is
being administered. M athem atical models and controls have been applied towards
developing strategies which would determ ine when and how much of a drug to inject to
produce a prolonged and effective therapeutic result [10], [11], [12], [23], [39]. However,
the combination of m athem atical models with real-tim e clinical d a ta could assist in
providing b etter quality control in dosing. Predictive models could further help in
identifying adverse events prior to the onset of signs and symptoms.
In recent years, clinical studies have been carried out for m easurem ents of the
uptake and clearance of engineered gold nanoparticles in the tissues of dosed mice
[18], [26], [27], [28], [29]. These devices are under consideration for a new therapy for
cancerous tum ors. Clinical trials in animals are currently underway to investigate the
therapeutic bioavailability of nanoparticles used in the treatm ent of these tum ors in a
technique known as nanoparticle-assisted phototherm al cancer therapy, such as in [26]
and [27]. The research presented here investigates th e development of m athem atical
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models to estim ate in real-time the circulation param eters of models, from which we
calculate the area-under-the-curve (AUC) and half-life towards a clinical application.
These particular variables can be telling of th e overall retention of th e nanoparticles
[17], [28], as will be discussed in C hapter 2.
In this dissertation, we present a framework for the least error models of the
experiments th a t can be created in real tim e (th at is, within th e tim e of which the
experiment is run). Many different modeling m ethods were considered for this work
th at dealt with separating th e body into different com partm ents (i.e. the reticulo
endothelial system, the tumor, the lungs, etc.)

[17], [20], [37], [38] and also those

th at dealt w ith only a single com partm ent (the entire body a t once) [5], [9], [14],
[15], [22]. It was decided, for this work, to model a single com partm ent. This is due
to a lack of clinical d ata for accum ulation in the tum or, clearance by th e Reticulo
Endothelial System, etc. W ithout this d ata is not possible to accurately model w hat
is happening in the separate com partm ents of the body. Several different models are
presented, each of which provides a best fit for different times in the experiments.
We start w ith a rational function model which mimics models th a t were found in the
literature th a t include both the uptake and retention phases [17]. We then show the
exponential model in order to have a model which focuses strictly on the retention
phase of the experiment. Also, in an effort to improve upon the skewed rational model,
an absolute value model is presented. Finally, a piecewise function is presented which
combines a certain desired shape for the injection phase of the experim ent and the
already found exponential best fit for the retention phase.
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Upon completion of these models, statistical tests were employed to determ ine
if the d ata were correlated enough to take averages w ithout losing generality. The
Spearm an Ranked Correlation test was done on several different pairs of d ata sets to
determine whether or not certain experim ental variables were related. The Wilcoxon
Signed Rank test was then perform ed to ensure th a t every value w ithin each individual
d ata set was statistically similar. We then averaged each model for each set of d ata
and created confidence bounds and prediction intervals. These averaged models, or
‘M aster Mice’, were calculated, along with the confidence and prediction intervals, so
th at, in future experiments, adverse reactions (such as allergic reactions or significant
clearance rates) may be detected w ithin the time of th e experiment and changes in
dosage rates can be made accordingly. The ‘M aster Mice’ also provide appropriate
data sets to test using the controllers th a t are discussed in C hapters 4 and 5.
A Linear Q uadratic Regulator (LQR) tracking controller (as discussed in [7]
and [4]) was then applied to the averaged models, or ‘M aster Mice’. This controller
was implemented on a delay differential equation model and included a tracking fea
ture to regulate the bloodstream nanoparticle concentration to a desired absorbance
value (measured in OD). Currently, the controller is only applied to the exponential
model as this is the most commonly referenced model in the literature. However, as a
delay differential equation takes the history of the function into account, the injection
phase of the piecewise model is included here. This controller is further analyzed by
changing the amount of the initial injection in order to investigate the possibility
of limiting the to tal amount of nanoparticles required experimentally. Dirac delta
functions are then used in place of the continuous tim e controller to determ ine the
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efficacy of a discrete am ount of injections to control the absorbance level as opposed to
the continuous injection used in the LQ R controller. Finally, a Proportional Integral
Derivative (PID) controller for a delay differential equation (similar to those discussed
in [33]) is applied to th e problem in an atte m p t to control not only th e absorbance
value (in OD) over time but the area under th e curve as well.
The goal of this work is to be able to use the model and controller in real
time during the injection and elim ination phase of nanoparticle adm inistration to a
subject. The use in real tim e situations would provide feedback in case of adverse
reaction or if the dose needs to be increased or decreased according to th e subject’s
reaction. Ideally, the feedback controller would also be used during the experim ent
so th a t the optim al level of nanoparticles would circulate through the bloodstream
for the maximum allowable time.
C hapter 2 contains background inform ation of th e experim ental work th a t is
has been done to obtain the d ata and also describes each of the least error models,
along with the m ethod th at was employed to obtain the models. C hapter 3 describes
the statistical tests th a t were run on the d ata and discusses what the results represent,
along with a description of the average models w ith th e corresponding confidence and
prediction intervals. The control strategies and results are discussed in C hapters 4
and 5. Finally, in C hapter
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we conclude w ith observations and future work.

C H A PTER 2
LEAST ERROR MODELS
2.1 E x p erim en ta l D esig n
The objective of the pre-clinical experim ent from which the d a ta reported here
was obtained was to investigate the pharm acokinetic properties of therapeutic gold
nanorods. These 40-nm diam eter gold nanorods were m anufactured by N anospectra
Biosciences, Inc (NBI) (Houston, TX ) and are used for the phototherm al ablation of
tum or cells [1], [32]. T hat is, the nanorods are first injected into the bloodstream ;
then, upon collection in the tum or, the nanorods are given laser treatm en t th a t causes
them to heat to the point of killing the vasculature of the tumor, thus killing the tum or.
They are used in the experiments from which the d a ta is collected specifically with
murine colon carcinomas. These tum ors are grown on the flank of th e mouse just
beneath the skin until the tum or reaches the desired size. Once the tum or was the
appropriate size, the nanorods were injected and circulation d a ta was collected.
The d ata was collected by the O ’Neal group in the Biomedical Engineering
program at Louisiana Tech University in collaboration with NBI. T he real-tim e blood
concentration of the nanorods was m onitored using a novel non-invasive optical device
similar to a pulse oximeter [26], [27], [28].
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This experim ental pulse photom eter,
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also referred to as th e ‘NanoTracker’, uses th e technique of multi-wavelength pho
toplethysmography [1]. The NanoTracker measures the attenuation of near-infrared
wavelengths as nanorods are introduced into th e pulsatile bloodstream of the subject
and quantifies the circulating dose in near real-tim e in term s of optical density units
(OD) [26], [27], [28]. An OD unit refers to the quantity of absorbance of the nanorods.
The quantity of absorbance of the nanorods is indicative of the actual concentration
of nanorods circulating a t th a t time.
The experiment in which the d a ta was collected employed two groups of ~20g
BALB/c mice to examine the variability of nanorod circulation param eters and their
effects on related clinical pharmacokinetic variables such as tum or uptake. T he ~100
OD nanorods were intravenously injected at dosages of either 4.5/xL/gm (lx ) or
9 /zL/gm

(2x) body weight at the rate of 18/rl/min. At discrete tim e points post

injection, th e NanoTracker was placed on the tail of th e mouse and m easurements
were taken a t regular intervals until which tim e the observed optical density reached
a level of 1 OD ±10%. The d ata was later used to produce a bioavailability curve
and to compute typical measurements of perform ance such as AUC and half-life. The
bioavailability curve th a t was produced here is not the same as th a t which is found
by any of the least error models presented in this chapter.

2.2 L east E rror M o d els
It is im portant to be aware th a t, as the measurements were taken at discrete
tim e intervals and not continuously for the duration of the experim ent, the highest
or lowest points in the observed d ata do not necessary reflect the actually highest
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and lowest points th a t occur in reality. For this reason, more points are interpolated
using the observed d ata points. This process is described in Subsection 2.2.1. The
d ata is separated into two phases: the injection phase, or uptake, and th e elim ination
phase, or retention, which refers to how long the nanoparticles are actually staying
in the body. Currently, the literature mostly focuses on modeling the retention phase
by itself [17]. As it is im portant for this study to model both phases of the data,
three different models are created and a minimal search algorithm is performed
using MATLAB® in order to find the best fit between the experim ental d a ta and
the m athem atical models.
2.2.1 Error D eterm in a tio n
The function against which the respective models were com pared was a piecewise exponential function. This was created by determ ining an exponential function
which fit each pair of consecutive experim ental d a ta points.

T he algorithm was

w ritten to insure the function started at zero for each set of d a ta and also term inated
at the final d ata point (as opposed to assuming an exponential decay or rise past th a t
point). For the sake of conciseness, this function will be defined as A(t).
Initially, the error was calculated using the standard Euclidian norm, shown
in (2 . 1 )

where N := total number of points in A(t). y — y := the error in the y-direction
between the model to be found and the approxim ated experim ental function A(t).
This calculation evolved to evaluating the error using th e standard R-squared value
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for ease of comparison to other models in th e literature and also because this is the
more generally accepted error calculation. T he R-squared value is defined in (2.2)
£ < ( ( * —Vi)2)

r>2 _ i

fn o\

R 1 r.Mvi - m ’
=

"

( 2 ' 2 )

where y — y := the error in the y-direction between the model to be found and the
approxim ated experimental function A( t ) and yi — y := the difference between the
function A(t) and the mean value of .4(f). A model which yields an R-squared value
close to one is considered a good fit and implies low errors.
Though utilizing the calculated R-squared as the value to be minimized when
finding each model was appropriate for comparison purposes, it proved to be a weak
determ ination of overall error between a model and A( t ) as it only took the error
in y-direction into account.
have

been a large

It was observed in th e models th a t though

there may

difference in the y-direction, the values in the x-direction

were

quite close. In order to b etter represent the overall error for each model, the Total
Least Squared (TLS) m ethod given in [30] was performed. This m ethod found the
orthogonal distance between each point on the particular model and th e nearest point
(considering both the x and y-directions) in A(t). The to tal error in this m ethod was
defined as the sum of these distances squared. As this value is com parable to the
num erator of (2 .2 ), in order to be able to com pare each error calculation with ease,
the ‘TLS-squared’ value is calculated by replacing the num erator of (2.2) with the
TLS error value. Both the R-squared and ‘TLS-squared’ error values are calculated
for each model th a t is presented and values close to one imply good fits.
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2.2.2 R a tio n a l M o d el
Both the uptake and retention phases of the d ata were initially modeled using
a rational expression. As this expression models both the uptake and the retention
phase, it is particularly useful for predictive purposes such as early diagnosis of
adverse reactions to the nanoparticles. After considering several different functions
(polynomials of varying degrees, logistic equation, and trigonom etric functions), the
following equation was found to represent the experim ental d ata well and yielded low
error when the aforementioned minimal search algorithm was performed:

with a, P, and

7

being real-valued param eters determ ined from the minimal search

algorithm and t tim e (in minutes). As an example, Figure 2.1 shows this model with
its corresponding R-squared value for one particular mouse.

Mouse 20111104B-3

Mouse 20111104B-3
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F igu re 2.1: Approximated rational curve found using R-squared (left) and TLS
(right)
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This function yields acceptably low R-squared values and gives a good esti
mation of the uptake and retention phases of th e nanoparticles. However, the peak
absorbance value (in OD units) is skewed towards the right of the experim ental peak
for each mouse modeled, and it also tends to show too sharp of a drop im m ediately
following the peak absorbance when com pared to experimental observations.

2.2.3 E x p o n en tia l M o d el
Though the rational model is useful for predictive purposes, an exponential
decay which models only the elim ination of nanoparticles from the bloodstream is the
more generally accepted model in pharm acokinetics [17]. Of course, even though the
nanoparticles are not drugs and are generally inert, they must still clear them , so the
exponential model which highlights the elim ination phase was naturally considered as
a possibility. This model begins at the peak d a ta point, where the nanoparticles are
at the highest observed concentration in the bloodstream . Dr. O ’Neal and his team
theorize th a t the reason for the sharp drop in concentration after th e nanoparticle
peak in the algebraic model is because of poorly coated nanoparticles th a t are in
the batch. As the nanoparticles m ust be coated w ith something to keep the body
from eliminating them immediately upon detection, the nanoparticles th a t are not
properly coated (and there are some in every batch), and therefore easily detected by
the body’s reticulo-endothelial system, will be elim inated very quickly. This model
helps to lessen th a t drop off by not taking the im properly coated nanoparticles into
account as much as (2.3). An exponential decay function is used:

11

C B( t ) = a * e ~ 0*t ,

(2.4)

where a and 0 are real-valued param eters and t is tim e (in m inutes). These param e
ters were found in the same way as those for (2.3) while only using the experim ental
d ata from th e retention phase. As with the rational model, this yielded low error
when compared to the experim ental data. Figure 2.2 shows th e exponential plot for
the same mouse as depicted in Figure 2.1. It is also of interest to find the area under
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F igu re 2.2: Approximated exponential curve found using R-squared (left) and TLS
(right)

the curve (AUC) of each fit for each mouse as it can be telling of the to tal uptake of
the nanoparticles in the body. W ith th a t in mind, while finding the best fit models,
code was also run to find the maximum values for the rational fit, the area under the
curve for both fits, and the half-life for the nanoparticle circulation in the bloodstream .
Ju st as the uptake can be found using the area under the curve, the retention is seen
by looking at the half-life [17]. The area under the curve was found using Simpson’s
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quadrature with th e best fit array and the half-life by finding the tim e a t which the
absorbance is half th a t of the maximum value of the best-fit model.

2 .2 .4 A b so lu te V alu e M od el
The rational model was useful in predictions but, though it yielded good Rsquared values, was found to be skewed towards the elim ination phase of the curve.
T hat is, it took more tim e on average in the prediction models to reach the maximum
absorbance th an was actually being observed in experiments. In an attem p t to solve
this problem, a new model was used th a t showed a sharper rise to help account more
properly for the accum ulation phase of the curve.

This function has been found

to yield similar R-squared values overall but showed a more realistic shape when
compared to the experim ental data. Several exponential values were tested before
arriving at the equation:
2

CB(t) = with a, j3, and

7

a * t 3 — (3 + /? +

3

7

*<4,

being real-valued param eters and t is tim e (in m inutes).

(2.5)
The

constants are found in the same way as those of (2.5) and (2.4). Figure 2.3 shows a
plot of this fit for th e same mouse displayed in Figures 2.1 and 2.2.

2.2.5 P ie c e w ise M o d el
In order to obtain a model th a t would have a still better fit for both the uptake
and retention phases, a concatenation of functions to create a piecewise function was
done. As it is the goal of this project to be able to create these models in real time,
it was necessary at this point to use functions th a t had already been found to yield a
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F igu re 2.3: Approximated absolute value curve found using R -squared (left) and
TLS (right)
good fit for either the uptake or retention phase. W ith th a t in m ind, the exponential
fit was used for the retention phase and different injection profiles were considered
for the uptake.
Four injection profiles per dosage group are considered in this work. T he first
is linear, thus indicating a linear rate, the second is a positive quadratic, indicating an
increase in th e rate of injection as tim e progresses, the third is a negative quadratic,
indicating a faster rate of injection initially th a t levels off tow ard the end of the
injection time window, and the last is an exponential curve, indicating an exponential
rate. The four injection profiles per dosage, denoted /*(£) with i = 1,2,3, 4, were
designed to satisfy the same conditions as those specified for (2.4), thus yielding
h(t)

= (^)t + a,

h{t)

= ( f ) ( t + v ) 2,

h{t)
I4(t)

=

+ a,
= e ^ M

- l ,

( 2 .6 )

14
with q from (2.4), t is time, and

77

equal to the injection time (10 minutes or 0.1667

hours unless otherwise specified). These profiles are shown for the average mouse
in each data set (lx and 2x) in Figure 2.4 and are described further in C hapter 3.
Each of these profiles are used to represent the injection phase of the experiment with

4.5

4.5

3.5

2.5

2.5

05

05

-0.5
t (hours)

I (hours)

F ig u re 2.4: Injection Profiles for lx Mouse (left) and 2x Mouse (right) (in OD)

the already found exponential function representing the retention phase. In order to
have a more ideal control effort, the negative quadratic injection profile is used here
yielding the equation
■( $)t 2 + a

:0 < t< ti
(2.7)

C B(t) =
q *e

4i) : t > ti

where a and rj are the same as in (2.6). This gives the model shown in Figure 2.5. As
this model is actually a concatenation of functions and is not found using a minimal
search algorithm, it is not necessary to compare the different error term s in this case.
These error calculations have essentially already been found during th e calculation of
the exponential model. For th a t reason, this model is only shown w ith its respective
R-squared value.
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F igure 2.5: A pproxim ated piecewise curve
2.3 R e su lts
There were several different models presented and each gave a different insight
into how the experimental d ata behaves in real time. T he R-squared values for each
model for each mouse were found using the residuals in the y-direction with the
interpolation experimental d ata points vs. the points found in each best fit model, as
described in Subsection 2.2.1. These values are shown in Table 2.1.
When analyzing the mean and median shown in Table 2.1 we can see th a t the
values for each model set are quite close with the exception of the piecewise models
where th e m ean= .759 and the m edian= .915. This discrepancy most likely implies
outliers in the d ata set for th a t model which are assumed to be caused by the weakness
in the R-squared value. It is im portant to note th a t, since only the vertical values
are considered in the R-squared calculation, some of th e values may be quite low
even though th e figures show th a t model appears accurate. The vertical values were
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Table 2.1: R-Squared Values per Mouse
Mouse
20111104A-1
20120120C-3
2 0 1 1 1 2 0 2 A- 0
20120120C-5
20111104A-3
2 0 1 1 1 2 0 2 A- 1
20111202B-1
20111202A-2
20120120A-0
20111104B-1
20111104A-5
20111202B-3
20111104B-3
20111202B-2
20120120D-0
20120220A-3-5
20120220A-5
Mean R 2
Median R 2

Rational
R2
0.681
0.499
0.558
0.559
0.479
0.438
0.562
0.734
0.185
0.819
0.665
0.802
0.793
0.711
0.580
0.563
0.537
0.596
0.563

Abs. Value
R2
0.809
0.861
0.936
0.862
0.945
0.933
0.941
0.704
0.815
0.672
0.672
0.652
0.936
0.853
0.963
0.920
0.961
0.850
0.862

Exponential
R2
0.998
0.867
0.993
0.972
0.928
0.972
0.989
0.919
0.933
0.984
0.979
0.992
0.997
0.991
0.978
0.983
0.982
0.969
0.982

Piecewise
R2
0 .2 1 2

0.947
0.908
0.771
0.925
0.892
0.915
0.276
0.931
0.132
0.350
0.639
0.947
0.987
0.958
0.979
0.976
0.759
0.915

considered as well in the TLS m ethod (as discussed in Subsection 2.2.1) though using
these considerations tended to produce very similar models as those found using the
R-squared calculation. T h a t being said, the m ean and median values shown for the
exponential models are considerably close to one, m eaning th at model is consistently
accurate. It makes sense th a t this model shows the m ost accurate results as it only
models the elimination phase when the injection phase appeared to be the m ain source
of error for th e other models. Due to th e lower R-squared values for the models th at
show both the injection and elim ination phases it can be assumed th a t the injection
phase of the experiment is more difficult to predict th a n the elim ination phase. This
is most likely because of the lack of experim ental d a ta points for this phase of the
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experiment.

The sparse d ata collection during the injection forces the models to

make more assumptions than are needed during the elim ination phase where more
d ata points were given. The absolute value model appears to be the most accurate
model which takes both the injection and elim ination phase into account. However,
as discussed above, the piecewise model appears to describe the d a ta accurately as
well, with the exception of the few values in the d a ta set already discussed.

C H A PT E R 3
STATISTICAL EVALUATIONS
W ith the best fits found as described in C hapter 2 for each of the mice for
each of the models, it is necessary to perform statistical evaluations to ensure first
th a t the results make biological sense and also to make certain th a t averages of each
d ata set can be taken. The Spearm an Rank Correlation test, described in Section 3.1,
was chosen to test how well certain values in the d ata compared to others which is
descriptive of the raw d a ta found in the experiment. The Wilcoxon Signed R ank test
described in Section 3.2 showed whether all of the least fits for a particular model
could be averaged to create a “m aster mouse” w ithout loss of generality. The nonparam etric tests were chosen due to the small d a ta sets and lack of norm ality w ithin
th e sets [31]. The freeware program R was used for this analysis.

3.1 S p earm an R an k C orrelation
The first test run was the Spearm an rank correlation in order to investigate
how well certain values within the d a ta correlated. The results are shown in Table 3.1,
with a p close to ± 1 implying a high correlation. The value p is a nonparam etric
measure of statistical dependance between any two variables.

As can be seen in

Table 3.1, almost none of the d ata comparisons yielded high correlation coefficients.
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While these results are of interest to the biological portion of the experim ent, they
do not have a negative effect on this analysis.
T able 3.1: Spearm an Rank Correlation Results
D ata Sets Tested
*max absorbance for lx rational model vs.
AUC for lx rational model
*max absorbance for lx abs. value model vs.
AUC for lx abs. value model
max absorbance for 2 x rational model vs.
AUC for 2 x rational model
m ax absorbance for 2 x abs. value model vs.
AUC for 2 x abs. value model
*AUC for lx exp. model vs.
AUC for lx abs. value model
*AUC for lx exp. model vs.
AUC for lx rational model
AUC for 2x exp. model vs.
AUC for 2 x abs. value model
AUC for 2 x exp. model vs.
AUC for 2 x rational model

P
0.2771084
0.3012048
0.6727273
0.60
0.5421687
0.5421687
0.8545455
0.8545455

The * in Table 3.1 implies th a t the exact p-value could not be com puted with
ties. As this warning came up when the test was run, it was appropriate to report it
here. However, since the outcome of th e test is dependent on p and not p, th e fact th a t
the p-value could not be computed on some of the tests is irrelevant. The first set of
tests run evaluated the level of correlation between th e maximum values calculated in
the models and the AUC for the respective model. As the highest of these correlations
found was 0.6727 it is clear th a t there exists no clear correlation between these values.
This result is not what was expected as it would seem reasonable th a t the higher
the maximum value of the model is, the higher the AUC would be as well. T h at
assumption, however, is not supported by this analysis.
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The second group of values (the bottom four in Table 3.1) test the correlation
between the AUC for th e exponential models and the AUC for rational or absolute
value models. Though the values for th e lx models are quite low, the 2x models
seem to have a high correlation. It is unusual th a t the different initial dosages would
produce such different results in this test but it is expected th at the exponential model
would have a good correlation with the other two. This analysis is taken into account
in Chapters 4 and 5 in the discussion of the different controllers th a t are presented.

3.2 W ilco x o n S ign ed R a n k
The Wilcoxon Signed Rank Test was performed on each individual set of data,
testing if the mean of the d ata is statistically equal to the median. T he null hypothesis
for the test on each d a ta set was th a t the median is equal to the m ean, which would
imply th a t the d ata is closely related w ith the alternative hypothesis being th a t mean
and median are not equal, or th a t the d a ta is not closely related. T he null hypothesis
was rejected if the found p-value was less than a (which was chosen to be 0.05) and
was accepted otherwise.

The results of this test are quite significant as negative

results would prevent th e analysis from moving forward for th a t particular d ata set.
The results from this test are shown in Table 3.2 with * implying the same warning as
was in Table 3.1. It is shown th a t the d a ta within each set are statistically similar as
the p-value th a t was found was higher th an the chosen a. Though the exact p-value
could not be determ ined for certain sets, the close calculation which was found was
determined to be a good estimate. As the sets were all found to be statistically similar
we are now able to average each set w ithout concern of misrepresenting the data.
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Table 3.2: Wilcoxon Signed R ank Test Results
D ata Set Tested
m ax absorbance for 2 x rational models
m ax absorbance for 2 x abs. value models
AUC for 2 x rational models
AUC for 2 x exponential models
AUC for 2x abs. value models
max absorbance for lx rational models
max absorbance for lx abs. value models
AUC for lx rational models
AUC for lx exponential models
AUC for lx abs. value models

p-value
0.7695
1.0
0.9219
0.9219
0.9219
*0.9441
*0.9441
*0.9441
* 1.0
*0.9441

3.3 C on fidence an d P r e d ic tio n In tervals
As all of the mice within each individual d a ta set were found to be statistically
similar, an average of each d ata set could be performed to create a “m aster mouse”
of all of the models. W ith these “m aster mice” , confidence and prediction intervals
were calculated using MATLAB®.
The difference between confidence and prediction intervals is an im portant
distinction to make. As an example, an 80% confidence interval implies th a t if 100
similar samples were drawn, in 80 out of

100

tests, the mean absorbance m easure

would fall in th a t interval. The confidence interval is a good indication of how well
the m ean of the d a ta has been determined. A prediction interval gives a range of
where the next d ata point sampled can be expected. T h a t is, for example, for an 85%
prediction interval, there is an 85% probability th a t the next sampled d ata point will
fall w ithin th a t range. This interval tells about the distribution of the data, rather
than the uncertainty in determining the m ean [2], [24].
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The confidence intervals were calculated at 80% and 90% for each d a ta set.
To find these intervals within each set, the absorption values a t each tim e point were
first averaged in order to create the m aster mouse for th a t d a ta set. The standard
deviation was then found using the built in MATLAB® function. For the lx data
sets, the 80% intervals were calculated at each tim e point by taking the average
absorbance ± 1.383 x standard deviation and the 90% bounds by average absorbance
± 1.833 x stan d ard deviation.

And for the 2x d ata sets: 80% bounds by average

absorbance ± 1.415*standard deviation, 90% by average absorbance ± 1.895*standard deviation. Each of these values were found in the standard t-distribution table
according to th e number of mice in each d ata set.
The prediction intervals for each d ata set were calculated a t 85% for each time
value so th a t a mostly sm ooth function was created for the upper and lower bounds
of the intervals. In order to calculate th e intervals, the absorbance values for each
time set first had to be arranged in increasing order. Once the d ata was in increasing
order, the central 85% of the d ata was taken to be the prediction set for th a t time
point.
For ease of comparison, the exponential models with their confidence and
prediction intervals are shown in Figure 3.1. Figure 3.2 shows th e lx and 2x rational
models with their respective confidence and prediction intervals, found in the same
m anner as the exponential intervals. Similarly found were the absolute value models
for the lx and 2x d ata sets, shown in Figure 3.3 and the piecewise models shown in
Figure 3.4. The intervals for these figures are shown with 90% confidence intervals
being the outer dashed lines and the 80% confidence intervals being the inner dotted
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line. The 85% prediction intervals are represented by the two solid lines surrounding
the center line (with the center line being the model itself).
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F igu re 3.1: Exponential lx Model (left), Exponential 2x Model (right)
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Average 2x Absolute Value Mode*
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F ig u re 3.4: Piecewise lx Model (left), Piecewise 2x Model (right)
The prediction intervals are different from the confidence intervals as they give
a range of where the next experim ental d ata point should fall as opposed to where
the mean of future d a ta sets would fall. The fact th a t the different intervals are close
in value is a good indication the experim ental d a ta sets are closely related. Each of
these intervals can be useful for the identification of untoward reactions when applied
in an experimental setting by comparing d ata points measured in real tim e with the
‘M aster Mouse’ for the respective dosage and its confidence and prediction intervals.

25
D ata points falling outside of these intervals would be a flag for further investigation
to determ ine untoward reactions a n d /o r to change to dosage scheme accordingly.

C H A PT E R 4
LQR TR AC K IN G CONTROL
As the least error m athem atical models have been found in C hapter 2 and
confirmed through the statistical evaluations in C hapter 3, we will now show how the
exponential model is utilized in a state space feedback control framework to regulate
the nanoparticles in the bloodstream . An equal tim e delay is also introduced in both
the state and control input for the purpose of studying th e alternate dosing strategies
shown in (2.6). While only the exponential model is being controlled, the inclusion
of the dosing strategies to account for the tim e delay creates a piecewise function
which is identical to the piecewise function described in C hapter 2.
Clearly, (2.4) is the solution to the simple first order, linear ordinary differential
equation
C B{t) = - 0 C B(t),

where Cs{t) = -—7 -- , Cb(£ = 0) = 7
at
decay rate, and time t =

0

G

IR in (2.4), —0

(4.1)

G

IR is the exponential

corresponds to the time when the nanoparticles are at

their highest concentration in the bloodstream , which occurs a t some delayed time
after the nanoparticle injection. T he two specific quantities of interest for comparison
between the experimental d a ta and the model are the nanoparticle half-life and the
AUC, referring to area under the bloodstream nanoparticle concentration curve. The
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half-life can be used to quantify nanoparticle retention, or how long the nanoparticles
remain in the body. T he area under the curve is im portant because it describes the
to tal uptake of nanoparticles by the body. Table 4.1 shows a com parison between the
experimental d a ta and the model for these two quantities of interest w ith an * implying
irrelevant results due to unrefined data, meaning th a t the set of experim ental d a ta
points did not provide enough inform ation to appropriately calculate the AUC. W ith
T a b le 4.1: Comparison Between Model and Experim ental Results
Mouse
ID

Model
R2

20111104A-1
20120120C-3
2 0 1 1 1 2 0 2 A- 0
20120120C-5
20111104A-3
2 0 1 1 1 2 0 2 A- 1
20111202B-1
20111202A-2
20120120A-0
20111104B-1
20111104A-5
20111202B-3
20111104B-3
20111202B-2
20120120D-0
20120220A-3-5
20120220A-5
mean
median

1 .0 0

0.87
0.99
0.97
0.93
0.97
0.99
0.92
0.93
0.98
0.98
0.99
1 .0 0
1 .0 0

0.98
0.98
0.98
0.97
0.98

Model
AUC
(OD*min)
2163
2725
1978
2916
1982
1931
2088
1769
2553
1100

1880
964
961
915
1815
1521
1206
1792
1978

Exper.
AUC
(OD*min)
1981
2446
1747
2628
1828
1716
1851
1480
2300
743
1609
701
773
*
1610
1212

1024
1603
1788

Model
1 / 2 -life
(min)
507
505
465
562
305
409
349
349
496
339
356
234
177
283
276
326
282
366
349

Exper.
1 / 2 -life
(min)
488
444
499
533
347
444
350
248
444
365
367
247
205
272
309
330
304
370
350

the mean and median for each d ata set shown in Table 4.1 being close together we
can assume th a t the d ata within each set do not have any extraneous values throwing
off the set as a whole. The controller presented later in this chapter and also those
presented in C hapter 5 aim to maximize the AUC and also lengthen the half life of
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the mouse (increasing the AUC and lengthening the half-life would theoretically go
hand in hand). After the half-life and area under the curve results were found for
each mouse, statistical tests for sim ilarity and correlations were run as described in
C hapter 3.
Because it is of interest to investigate different injection rates, the rate effects
on nanoparticle bioavailability, and m aintaining the bloodstream nanoparticle con
centration within an established therapeutic window, (4.1) is posed as a controlled,
delay differential equation (DDE). Specifically of interest is the optim al control of the
system with equal delays in both th e state and control input. T he general theory for
the LQR control problem related to delay systems can be found in [6 ], [8 ], [13], [35],
[36]. The model and control frameworks presented here will follow the more recent
formulation presented in [7]. The system of interest is given by
C B(t) = ~ P C B{t - h ) + bu(t - h ),

(4.2)

subject to th e history function C B(s) = 4>(s)

G

where h is the tim e delay in hours, C B(t)

IR1 is th e system sta te representing

G

C({—h, 0]; IR1) for all s

concentration of nanoparticles in the bloodstream , u(t)
6

G

G

[—h, 0],

IR1 is th e control input,

is a real-valued constant control input multiplier, and —(3

G

IR is the exponential

decay rate. W ith the inclusion of a delay in th e state, (4.2) is an infinite-dimensional
system (see, for example, [25]). This means th a t the function space has a basis set
which is infinite which further means th a t the function cannot be represented using a
finite set of simpler functions. From a practical standpoint, note th a t the tim e delay,
h, will correspond to the length of tim e over which the nanoparticle injection is given,
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and different history functions (p(s) (the same as those functions given in ( 2 .6 )) will
correspond to the different injection profiles being considered.

4.1 C o n tro l S tr a te g ie s
W ith (4.2) being a linear system, standard linear quadratic control techniques
will be employed. The solution to this control problem, with equal tim e delays found
in both the state and input, is found in [7] and summarized here, with appropriate
modifications made to include tracking, sim ilar to the derivation in [16]. T he specific
control objective of interest includes o u tp u t tracking, for the purpose of regulating the
bloodstream nanoparticle concentration to lie w ithin a specified therapeutic window.
This will be analyzed for multiple injection profiles, i.e. rates.
In considering a general linear system with tim e delay
(4.3)
with the usual assumptions as described in [7], the control im plem entation involves
a Linear Q uadratic Regulator (LQR) state tracking design, where the quadratic cost
function to be minimized is
J

= jM O l’VM O] + J

J

ut

(s ) R ( s )u (s ) d s

(4.4)

and the tracking problem reduces to a disturbance-rejection problem of the form
(4.5)
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where xi(t) = x(t — h) = £(f — h) — £(t —h ), ui(t) = u(t —h), w(t) is represented by
w(t) =

| ^ 0,

(4.6)

f is the state of some original dynamical linear system of interest,
i (t ) = A 0 (t)€(t - h) + B 0 (t)u(t - h) + z,
£ is the known desired state target of (4.7), and

2

(4.7)

is zero-mean, Gaussian, w hite noise.

The Ham iltonian for the optim al control problem (4.4), (4.5) is defined as
H(x,u,q.t) =

~ u T R( t ) u + ^ x T L(t)x
(4.8)
+qT [A(t)xi + B( t ) u i + w\.

For the purpose of minimizing the H am iltonian with respect to u, the gradient of
(4.8) is set equal to zero. Then solving for u yields the optim al control
u* = - R r \ t ) M T {t )BT {t)q(t),

(4.9)

du (f 1
where M( t ) := ——^—. Selecting a general quadratic form
du
J*(x, t) = ^-xT (t)Q(t)x(t) + bT (t)x(t) + c(t)

(4-10)

for the solution to the Ham ilton-Jacobi optim ization equation, to account for the
disturbance term w(t), yields the co-state
Q(t) = -

8

J*(x t)

= ~Q( t ) x ( t ) - b{t).

(4.11)

31
Then, with arguments of variables om itted from this point forward in the derivation
for conciseness, the Ham ilton-Jacobi optim ization equation becomes
j < - x L x +, -L,T;
-x Qx — bi.T„
x —xc____
= min
u Ru

1

2

u

I2

2

+(•—Q x — b)T ( Ax\ + B ti\ +

(4.12)
>

thereby yielding the optim al control
u* = R - ' M 1 B 1 (Qx + b).

(4.13)

Therefore, values for Q , M , and b m ust be determ ined. To determ ine Q, consider the
. dq{t)
dH , . ,
u
co-state equation —;— = —-r—, which yields
at
ox
Qx + Q x + b = L x + A M i q ,

(4-14)

Qx i
where Mi := ——. Now substituting (4.11), (4.5), and then (4.13) into (4.14) yields
ox
Qx + Q A x ( t - h ) + Q B ( R ~ l M TB TQx + R ~ l M T B Tb)
(4.15)
+Qw + b = L x - A TM l Qx - A TM 1b.
Differentiating (4.15) with respect to x and simplifying because M is th e identity
m atrix per th e argument in [7] produces the quasi-Riccati equation
Q = - Q M XA - Q B R ~ l B TQ + L - A t M 1Q,

(4.16)

where M x = 0 for t G [0, h) and M i = / for t > h, per [7]. Note th a t while th e co-state
selected in this work differs from th a t in [7], to accommodate for a control tracking
objective here, the argum ents to determ ine the values of M and M\ are identical.
To determine b, the optim al control (4.13) is substituted into the H am ilton-Jacobi
equation optim ization (4.12) and different powers of x are equated to obtain
b = [ A + B R ~ 1B TQ}Tb + Qw.

(4.17)
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Note th a t th e solution for c in (4.10) is irrelevant for th e control design sought here,
and thus, the differential equation is not shown. Because of the boundary conditions
J*(x, T) = ^ [ x ( T ) ] t i / j [x(T)] for all x, there also exist the boundary conditions Q ( T ) =
—ip and b(T) = 0. After the com putation of Q and b, the optim al control law is w ritten
as
u* = R - l B TQ { ^ - i ) + R ~ 1B Tb,

(4.18)

which is then implemented in (4.5).

4 .2 N u m erica l R e su lts
The numerical results presented here correspond to each of th e ‘M aster M ice’
presented in C hapter 3. This is because it is desired to consider the predictability of
nanoparticle bioavailability for individual ‘patients’ and, therefore, predicting for the
average mice is the m ost appropriate way to test the method. T he param eters of best
fit for (4.1) were determ ined to be

7

- (3.2475,4.1573), /? = (0.135, 0.095),

for the respective lx and

2x

(4.19)

models following an injection th a t began ten minutes

earlier with the injection profiles described in (2.6). Because gold nanoparticles are
devices, as opposed to medications, and only activated through laser, there is no
maximum nanoparticle level for a patient. However, because it is desired to expand
this analysis to many drugs and treatm ents, it is im portant to minimize the excess
dosages of the nanoparticles.

It also efficient from an industrial point of view to
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limit the total dose as nanoparticles do cost money to create. Also, the system is
not controlled on the time interval (0,0.1667) hours, so the area under the control
curve is only computed on [0.1667,20] hours. It was decided to end the model at
20

hours as the absorbance value has dropped below functional levels by th a t time.

The controller plots for each of the injection profiles can be found in Figures 4.1 and
4.2 for the lx and 2x ‘M aster Mice’, respectively. T he plots show no distinguishable
visual difference between the controllers required by each of the injection profiles.
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To calculate the control effort required to achieve each of th e injection profiles
and steer the bloodstream nanoparticle concentration to .5*maxiinum absorbance over
the course of a

20

hour tim e interval, the area under the absolute value of the control

34

.1

•1

•1.5

■1 .5

-2

-2

-2.5

-2 .5

?

f

5 -4.5
-5

-5

-5.5

■5.5

-6

-6

0

5

10

15

-6.5

20

0

5

10

15

20

15

20

lime (hours)

time (hours)

.1

•1.5
-2

•2.5

-2.5

s
I
t
I
5

1
1

~3-5

I -•
-4.5

-5
-5.5
-6

-6.5

0

5

time (hours)

10

lime (hours)
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curve u(t) is added to th e area under the corresponding injection profile curve. These
results are found in Table 4.2. The required control effort is quite similar for each of
the injection profiles, with the positive quadratic rate requiring the least am ount of
nanoparticles for each dosage group. Note th a t for all t, the control effort required
for the various profiles follows the order I 2 < I 4 < I\ < I 3 for each dosage group.
However, for t

G

[—0.1667, 0], the control effort required for

injections for each dosage group while for t

G

/3

is the largest of all the

[0.1667, 20], the control effort for

/ 3

is

the smallest of all the injection profiles. It appears th a t the negative quadratic rate
of injection found through using the

/3

profile allows th e bloodstream nanoparticle

concentration to “build up” so th a t fewer nanoparticles are needed later to achieve
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the desired target, thus providing for a more efficient use of resources. I\ follows
a similar pattern for each dosage group and therefore also appears to provide for a
more efficient injection. Given these results, it was determ ined th a t using the negative
T a b le 4.2: Control Efforts for Corresponding Injection Profiles (OD)
Injection
Ih(t)
Ih(t)
Ih(t)
iu(t)
/ 2 i(f)
/ 2 2(<)
/ 23( 0
I 24(t)

t e [-0.1667,0]
0.2707
0.1805
0.3609
0.2076
0.3465
0.2310
0.4620
0.2558

t € [0.1667,20]
64.3755
64.4558
64.2951
64.4321
97.2718
97.3561
97.1875
97.3386

Total Effort
64.6462
64.6363
64.6560
64.6397
97.6183
97.5871
97.6495
97.5944

quadratic injection profile is the most efficient. Using this injection, (4.2) was plotted
and shown in Figures 4.3 and 4.4 w ith their respective uncontrolled models for ease
of comparison.

Controlled Exponential Model

Uncontrolled Exponential Model
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F ig u re 4.3: Controlled lx Model (left), Uncontrolled lx Model (right)

4 .3 D o s a g e C o n v e rs io n
These models control the absorbance level (in OD) of th e nanoparticles over
time but it is necessary to convert the values from the measurement to /uL else, as
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Controlled Exponential Model
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F ig u re 4.4: Controlled 2x Model (left), Uncontrolled 2x Model (right)
injections are measured in fiL and not OD, the results are not useful in a real tim e
experiment. In order to accomplish this, the peak absorbance values from the lx
and 2x ‘M aster Mice’ along with the /jL injected were plotted and different functions
were fitted to th e plot. The exponential function (4.20) was found to be the most
reasonable:
f ( x ) = 0.6533x°'3564,

(4.20)

where f ( x ) =absorbance in OD and x = am ount injected in y L. Inversely (4.21)
f ( y ) = 3.3019z/2'8058,

(4.21)

gives the opposite conversion where f ( y ) = am ount injected in //L and y =aborbance
value in OD. These equations yield values consistent with w hat is expected exper
imentally asthe absorbance

value rises quickly w ith th e initial

injection and then

begins to leveloff over time. A sample table of points isgivenin Table 4.3
plot of (4.21) is given in Figure 4.5.

and the
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OD to nL Conversion
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F ig u re 4.5: OD to /xL Conversion
T a b le 4.3: Sample Values using the OD to /xL Conversions
£fL injected
0

90
180
360
720

(
(
(
(

lx dose)
dose)
4x dose)
8 x dose)
2x

R esultant absorbance (OD)
0.6533
3.2475
4.1575
5.3233
6.8150

Using (4.21), the total am ount of /xL needed to m aintain the controller in the
model given in (4.2) was calculated and those values are given in Table 4.4 along
with the am ounts used in experiments for th e purpose of comparison. These values
were determined by first converting the absorbance values from OD to /xL for both
the controlled and uncontrolled models, then summing the difference between the
controlled and uncontrolled models of the converted values. The injection was found
this way because, as th e uncontrolled model gives the absorbance values when no
injection (outside of th e initial bolus injection) is made, the converted values from
the uncontrolled model need to be subtracted from th e calculation to ensure th a t
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only the actual injection amount necessary in the controlled model is found. We are
basically finding th e area between the pL curves for the controlled and uncontrolled
models.
T a b le 4.4: pL of N anoparticles Required per Model
initial
absorbance (OD)
3.2475
4.1573

target
absorbance (OD)
1.6238
2.0789

uncontrolled model
to tal dose (/rL)
90
180

controlled model
to ta l dose (fiL)
234.64
1080.92

The values in Table 4.4 reveal th a t using this m ethod w ith the same initial
injection as is used in the uncontrolled model we see th a t the controller requires quite
a bit more fih to be injected than is ideal. However, as the absorbance level was kept
a t an ideal point with this m ethod, it is worth investigating further to a ttem p t to
lower th e overall control effort and, therefore, lower the necessary injection amount.

C H A PTER 5
CONTROLLER ANALYSIS
Because, in an experim ental setting, each patient will have different reactions
to a treatm ent and will need to be treated accordingly, it is im portant to investigate
several different control strategies. This will provide more tools th a t can be called
upon when this analysis is applied in real-tim e in an experim ental setting. Using
different strategies also helps to analyze the efficacy of any specific controller.

5.1 Further In v e stig a tio n in th e L Q R C on troller
Since the controller presented in C hapter 4 tracked efficiently, it was also of
interest to consider a lower initial injection so th a t the to tal injection over tim e could
be kept to minimum. Though it is unlikely th a t the am ount of gold nanoparticles
could ever build to a lethal level, it is im portant to look ahead to other treatm ents
th a t may be able to be used w ith this analysis.

Minimizing the injected am ount

needed will also help to reduce cost of treatm ent regardless of the treatm ent being
used. W ith this in mind, each model was also run w ith an initial injection set to half
of the original maximum absorbance of the respective models. T h a t is, as the goal
of the controller is to track to half the maximum absorbance, these models are now
trying to track to the initial injection value. These plots are shown Figures 5.1 and
5.2 with their respective uncontrolled models. These models show th a t th e applied
39

40
controller is able to to m aintain the absorbance level of the nanoparticles a t a level
which is more acceptable th an the uncontrolled models. As the LQR controller is
designed to run in an optim al tim e frame, it is encouraging th a t th e controller has an
effect on the exponential decay model.

T he dosages required for these control efforts

Uncontrolled Exponential Model

Controlled Exponential Model
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F igu re 5.1: Controlled lx Model (left), Uncontrolled lx Model (right)
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F igu re 5.2: Controlled 2x Model (left), Uncontrolled 2x Model (right)

are presented in Table 5.1 along w ith those from the controller shown in C hapter 4
for ease of comparison. The dosages are found using the same process as th a t for
the controller described in C hapter 4. The injections over time are shown in Figure
5.3.

The values presented in Table 5.1 show th a t using a lower initial dose gives a
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Required Dosage Over Time

Required Dosage Over Time
our
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F ig u re 5.3: Controlled lx Model (left) and 2x Model (right), in n L
T a b le 5.1: Total Dose of Each Control Strategy

initial
absorbance (OD)
target
absorbance (OD)
LQR control
total dose (fiL)

lx

2x

half lx

half 2 x

3.2475

4.1573

1.6238

2.0789

1.6238

2.0789

1.6238

2.0789

234.64

1080.92

65.25

299.1

significantly more efficient m ethod of control in term s of total injection. For the 2x
model, the percent error between the controlled model and the tracking targ et is only
18.53%. However, for the lx model, th e calculated percent error is 50.15%. The low
percent error for the 2 x model is promising but the high error for the lx model shows
th a t this m ethod may not be reliable when m any different dosage groups are being
considered. A model which requires a slightly higher overall injection but consistently
keeps the absorbance closer to the tracking target may be preferred. Of course, too
high of an overall injection is not ideal either.
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5.2 A n a ly sis o f ‘C o n tro l’ U sin g D irac D e lta F u n ctio n s
Though the controller discussed in Section 4.1 is interesting m athem atically, it
can not be easily replicated in a real tim e experiment w ith mice (which is im portant to
realize as anim al testing must be performed to confirm results before hum an testing
can take place), mainly because the controller is a continuous feedback controller
rather than a discrete controller. A discrete controller may also be useful in hum an
testing as it may be simpler to detect untoward reactions with this type of control
strategy than it would be with a continuous tim e control. W ith the injection not
happening continuously, any untoward reaction would also be minimized when using
this strategy. For these reasons, a good next step was to control the exponential
function described in (4.1) using several Dirac delta functions to m athem atically
replicate bolus injections given at different tim e intervals. This equation is similar to
(4.1) and is given by
Cs{t) — —0 Cs { t ) + m\ 5( t — h) + m2<5(f — 2 h) + m^8{t — 3 h)
(5.1)
+ m 4 (5(t —Ah) + m^8(t — 5 h) + m(,8{t — 6h),
where C b {1) =

= 0) =

7

G IR in

(4.1), —{3 e IR is the exponential

decay rate, h is the tim e delay for the injections in hours, and m* corresponds to the
m agnitude of the corresponding injection (represented by the Dirac delta functions)
and is measured initially in OD and then converted to /iL. m i, m 2, m 3, m 4, m 5, ra6,
and h were found by minimizing the TLS error th a t is calculated by comparing the
solution to (5.1) against a constant function which was set equal to half the maximum
value (which is considered to be in the therapeutic window for the nanoparticles),
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following the examples in [21]. Finding these param eters proved to be more difficult
than using th e search algorithm described for the models in C hapter 2. First, (5.1)
was solved analytically with a differential solver in MATLAB® and then evaluated
using different values for each unknown param eter until a minimum error was found.
The resulting plots over time are shown in Figures 5.4 and 5.5 for the lx and 2x
models, respectively. These plots show th a t several discrete injections are capable
(for both th e lx and

2x

models) of m aintaining the absorbance value (in OD) at a

level which would be considered within the therapeutic window of treatm en t for much
of the experim ental tim e frame.

Absorbance Over Time with Dirac Delta Functions
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F igu re 5.4: lx Exponential Decay with Dirac Delta Functions

Table 5.2 shows the time between each injection given and the am ount per
injection.

It was decided to limit the num ber of injections to six plus the initial

injection. This was done for the purpose of feasibility in a real world setting. Of
course, infinitely many injections would provide practically no error b u t th a t is not
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F ig u re 5.5: 2x Exponential Decay with Dirac Delta Functions
currently experimentally replicable. The tim e between injections was also restricted
to be a constant value instead of varied. Tests were run with variable tim es between
injections but these (much like having more injections) showed to take longer to run
than would be reasonable in a real world setting. Having variable tim e steps, despite
the longer time, did not provide significantly more effective ‘control’ of the exponential
decay when compared to the constant tim e step. In the case of Dirac delta functions,
the to tal injection am ount is a simple sum of the each individual injection as this is not
a continuous time controller. It is obvious from the values found in this analysis th at
having multiple smaller injections should provide a more efficient m ethod of keeping
the nanoparticle concentration within the assumed therapeutic window and would
theoretically require a smaller injection am ount overall than the original m ethod of
only one injection. W hen comparing the values from Tables 4.4 and 5.2 it seems clear
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Table 5.2: Results Using Dirac D elta Functions
Time between injections
Initial Injection
2nd Injection (m i)
3rd Injection (m 2 )
4th Injection (m 3 )
5th Injection ^ 4 )
6 th Injection (m 5 )
7th Injection (m$)
Total Injection Am ount
Experim ental Injection

1.053hrs
16.172/iL
3.395//L
2.561^L
2.581^L
3.015/^L
4.184//L
34.161^L
66.069/iL
45.0/iL

0.567hrs
28.722pL
4.480^L
4.840^L
4.120^L
3.869//L
12.833^tL
56.939^L
115.802/xL
90.0/iL

th a t the use of th e Dirac delta functions as opposed to one continuous tim e controller
is a more efficient choice in term s to tal am ount of /iL of nanoparticles needed.

5 .3 P ID T racking C o n tro l o f th e E x p o n en tia l D eca y
The controller presented in C hapter 4 was determ ined to be appropriate for the
given model. However, it was also of interest to investigate the use of a PID tracking
control as it is a common control strategy used in th e engineering and industrial
settings [19]. W ith a PID tracking control like the one presented in [33] we can
evaluate the possibility of tracking the model to a specific absorbtion value and also
limiting the area under the curve so th a t the to tal injection is kept to a minimum.
The model to be controlled is the same as th a t in C hapter 4 and given by (4.1).

5.3.1 S etu p o f th e P I D C on troller
For this controller, the delay is only included in the control function and the
model (in the tim e domain) is then generally presented as
x(t) = A( t ) x(t ) + B( t ) u ( t —d),

(5-2)
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where d represents the tim e delay. Unlike th e LQR controller presented in 4.1, the PID
controller utilizes three different gains, kp, kt1 and k d which represent the proportional
gain, integral gain, and derivative gain, respectively. The control function u in the
tim e domain is given by
(5.3)
where kp, kr, and kd are the gains to be found later and e(t) is m easured reference
error tim e signal given as e(t)

r —y with r being the target o u tp u t and y the actual

output. Each gain has a different purpose w ithin the control setting, as discussed in
[19]. The proportional control, kp, is used when the action of th e controller needs to
be proportional to the m agnitude of the error signal, e(t). The integral control, ki, is
used in order for the controller to correct for any steady offset from a reference signal
value. The derivative control, kd, uses the rate of change of the error signal, e(t), to
increase the overall control effort.
Solving this problem in the tim e dom ain is overly complex; however the use
of a Laplace transform into the frequency dom ain converts (5.2) into an algebraic
equation, such as in [4]. As (5.2) and (5.3) are linear combinations of functions (even
though those functions are not necessarily linear) and thanks to the linearity property
of the Laplace transform (as described in [4]), the transform of each of these equations
is equivalent to linear combination of transforms. T h a t is, the transform of a linear
combination is a linear combination of transform s. Transforming (5.2) yields
(5.4)
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Solving for X (s). (5.4) is represented by
(5-5)
with A: = —j , L = d, and T = —U. .4 < 0, &,T > 0 ensures th a t the problem is
open loop stable by th e theorem s set forth in [33] and can therefore be solved using
the described m ethods in the text. U (s) is found by transform ing (5.3) yielding
U(s) = kpE(s) + k i E ( s ) - + kdsE(s)]
5

(5.6)

therefore the control transfer function is given by
C(s) = ^ \ = kp + ^ + kds ,
E( s)
s

(5.7)

which is now an algebraic equation and not an integro-differential equation. Using
the Laplace transform has also taken the delay term in (5.2) and transform ed it to
an exponential decay in (5.4).

5.3.2 S ta b iliza tio n o f P ID P a ra m eters
Following a main result in [33], we know th a t the range of kp values for which
the open-loop stable problem can be stabilized using a PID controller is given by the
condition
1
1i
,i
1 TtT
—a s in ( a ) — cos(a)
~ k < k ’ < k Lj

(5.8)

where a satisfies the equation
ta n (a ) = -

T

(5.9)
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with the restriction a £ (0, 7r); a is found using th e Bisection m ethod in this work.
These values of kp are then used in
T
kkp + cos(z) — —z sin(z) = 0.
where the value

2

(5.10)

is also found using the bisection method. As there is a range of

possible values of k p, it stands to reason th a t there are also many solutions to (5.10).
These solutions, z j , are then used in
f

12

1

bj ( z j )

=

L

kzj

r sin (zj)

t

+ —Zj cos (zj)
Lj

i

(5'n )

with distinct solutions being found for each solution of (5.10). W ith these values, we
now have all the necessary inform ation to determ ine the conditions for the stabilizing
regions ki and kd- For all whole num ber values of j where j £ [l,length(fcp)], these
conditions are given by
ki

>

0

kd

>

m- j k i +b j ,

(5.12)

kd < m 2jki + b2j
The following algorithm was coded in MATLAB® to find each set of possible values
and is given in [33].
1. Initialize kp = —£ and step =

77^ ;,

where N is the desired num ber of points;

2. Increase kp as follows: kp + step (this was done using a while-loop);
3. If kp < k u then go to step 4. Else, term inate the algorithm;
4. Find the roots z x and z2 of (5.10);
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5. Com pute the param eters

rr ij

and bJ: j = 1,2 associated w ith the previously

found Zj by using (5.11);
6

. Determine the stabilizing region in the ki — kd space using (5.12);

7. Go to step

2

;

Following these conditions creates different trapezoidal or triangular shaped planes
for each value of kp. These planes are shown in Figure 5.6 for the system under
consideration here.
A r » » o f S tt O z t t o n

Aiwe ef 8 W * z e M n

F ig u re 5.6: Areas of Stabilization for the lx model (left) and 2x model (right)

5 .3 .3 R e s u lts U sin g t h e P I D C o n tr o l
W ithin the areas of stabilization shown in Figure 5.6, all values of k p, kx, and kd
will provide a solution of (5.2) and (5.3); this means th a t, since the param eters are real
values, there are as many solutions as there are combinations of th e param eters. To
be certain th a t a solution of minimal error was found, each com bination of param eters
was considered and the overshoot (in regards to th e target of th e tracking control)
was found. Also, the norm of the difference of each solution vector and th e tracking
target was calculated. Each solution was first found by solving (5.5) in th e frequency
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domain and then performing a numerical inverse Laplace transform using the code
found in [3], which then provides the solution to (5.2) and (5.3) in the tim e domain.
The overshoot, plotted against the respective function’s kt and kp values is shown
in Figure 5.7. This figure shows th e wide range of overshoot values th a t are found
when each com bination of param eters is considered. T he average overshoot for each
model is on the m agnitude of a t least

1 0 14

meaning th a t the choice of param eters is

of utm ost im portance when using this control design.
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F ig u re 5.7: Overshoot for lx (left) and

2x

(right) models

The solution sets utilizing of ku kp, and kd th a t provided the lowest norm
calculation were considered desirable and are plotted in Figures 5.8 and 5.9. The
solution set with the lowest norm was chosen in an effort minimize the stabilizing
tim e of the model and th at with the lowest overshoot was chosen in an effort to
minimize the overall required injection.

The values in the solution set were then

converted from OD to fj,L using (4.21) and plotted in Figures 5.10 and 5.11. It would
also be considered appropriate to use the overshoot as the performance criteria for
this controller because it is desired to limit the to ta l injection am ount while still
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tracking th e absorbance to a desired value and lim iting the overshoot accomplishes
this. However, limiting the overshoot will not necessarily lessen th e stabilizing tim e of
the model and therefore may not allow th e nanoparticles to build in th e bloodstream .
The plots shown in Figures 5.8 and 5.9 show th a t the controller tracks to the
desired value within the time frame of the experim ent and with the initial absorbance
value of 0 OD. The initial absorbance value for this controller is set to zero in order
to more closely follow the examples given in th e literature. However, because the
initial absorbance value will typically be zero in an experim ental setting, this is an
appropriate condition to follow. There is also very little oscillation in the plots shown
in Figures 5.8 and 5.9 and it stabilizes to th e target very quickly. W ith the absorbance
values initially being below the targ et (unlike past strategies), it is likely th a t the level
of required injection would be lower when com pared to the other strategies.
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While the models th a t give the minimum norm calculation do not necessarily
show a faster stabilizing time th an those w ith th e minimum overshoot, they do show
quick stabilizing times and are an appropriate way to guarantee a m inim al (if not
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th e most minimal) stabilizing tim e when used with future models. C alculating the
injection over time for these models was a two p art process: the first to account for the
injections made before the model stabilizes and the second is for the tim e following
th e stabilization of the model (when m easured in OD). For th e first portion of the
calculation, the injection was found using th e conversion given by (4.21) with the
absorbance value at each time point. The injection am ount necessary to build to the
absorbance at any one tim e point is then equal to difference between /iL at th a t time
point and the //L at th e preceding tim e point. Once th e controlled model stabilizes
to the tracking target, this m ethod to find the injection amount is no longer useful as
the difference in n L between one tim e point and the next would be very close to zero
and, therefore, not an accurate description of the nanoparticles needed to m aintain
the absorbance at a particular value. For this reason, once the model reaches the
point of stabilization, the am ount of nanoparticles needed is found in th e same way
as it is for the LQR controller. T h at is, we are basically finding the area between
the /rL curves for the controlled and uncontrolled models, where the uncontrolled
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model is the exponential decay function given by (2.4) with an initial value equal to
the tracking target and a horizontal translation to account for the tim e taken for the
model to stabilize to th a t target. T he values found are shown in Figures 5.10 and
5.11 and the to tal injection am ounts are given in Table 5.3.
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5.4 C om parison o f th e M e th o d s o f C on trol
Aside from simply comparing the plots produced by each m ethod of control,
the only way to properly compare the models is to compare the to tal error for each
model (which is found using the Total Least Squares m ethod in [30]) along with the
required overall dose (in /iL) for each model. Each of those values was found and
given in Tables 5.3 and 5.4, respectively.

Judging by th e error alone, it would seem

T able 5.3: Total Dose of Each Control Strategy

initial
absorbance (OD)
target
absorbance (OD)
LQR control
total dose (/iL)
Dirac delta
to tal dose (/iL)
PID control(w /0 initial OD)
total dose (/iL)

lx

2x

half lx

half 2 x

3.2475

4.1573

1.6238

2.0789

1.6238

2.0789

1.6238

2.0789

234.64

1080.92

65.25

299.1

127.3

235.33
w /m in norm
w /m in overshoot

66.07
242.58
222.80

115.08
498.25
467.31

*

T able 5.4: Total Error According to Initial Absorbance
Initial / Target
Absorbance (OD)

No
Control

0 / 1.6238
0 / 2.0789

*
*

3.2475
4.1573
1.6238
2.0789

/
/
/
/

1.6238
2.0789
1.6238
2.0789

430.81
472.66
572.93
695.07

PID Control
w /m in
overshoot
2.4529
0.3820
LQR
Control
178.47
539.72
140.89
26.53

PID Control
w /m in
norm
0.2957
0.5666
Dirac
delta
285.73
432.52
39.44
105.9

th a t the PID control (whether by using the minimum overshoot or th e minimum
norm) is the most efficient. However, because of the methods involved in stabilizing
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the PID controller, it requires several minutes to hours to run; as opposed to th e other
strategies which require seconds to minutes. The PID controller also requires a rather
high total dose which is expected as it is the only m ethod of control analyzed th a t
held the absorbance level to the desired target. This is not ideal when future work is
considered as we would want to apply the controller during a real-tim e experiment.
W ith this being said, it would appear using Dirac delta functions as the m ethod of
control is the most efficient as it provides low error and a low to tal injection. This
m ethod is also able to keep the absorbance level close to the target for the bulk of the
experiment (as can be seen in Figures 5.4 and 5.5) and should be easily replicable in
an experimental setting with some animals when a continuous infusion is not possible.
W hen a continuous infusion is a possibility, the LQR control strategy is an efficient
choice as well.

C H A PT E R 6
CONCLUSIONS A N D FU TU R E W ORK
6.1 S u m m ary an d C on clu sion s
In this work, several different models are presented to represent th e nanopar
ticle concentration in the bloodstream over tim e via absorbance m easurem ents. The
algebraic model is described in (2.3) and plotted for the particular mouse in Figure
2.1. Though it was a good starting point, this model was found to have a low Rsquared value for each mouse modeled. It was determ ined th at, overall, this model
skewed the tim e of maximum absorbance to a later tim e point; it also tended to yield
low maximum absorbance predictions. For those reasons, a new model was used.
The absolute value model described in (2.5) and plotted for the particular
mouse in Figure 2.3 has shown to improve upon th e issues found w ith the rational
model. As the absolute value model is capable of a much faster rise in the dependant
variable, the skew of the tim e of maxim um absorbance shown in Figure 2.1 was
better accounted. This model also showed b etter overall predictions of the maxim um
absorbance.

However, much like the algebraic model, this model was unable to

account for the false ‘peak’ in nanoparticle uptake; this refers to the high maximum
absorbance th a t quickly drops off, most likely due to poor coating of some of the
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injected nanoparticles. As neither the algebraic nor the rational model were able to
account for this perceived error, the exponential model was created.
Figure 2.2 plots (2.4) for the same particular mouse of the above two models.
This exponential model not only accounts for the false ‘peak’ of nanoparticles, but
also gives a more ‘close u p ’ view of the retention phase of the experim ent; this is of
particular interest for th e control effort portion of this research. As the goal of the
control effort for the current model is to maximize the retention of nanoparticles in
th e bloodstream, the control effort is focused on the exponential model only. Using
this model and the injection profiles described in (2 .6 ), th e piecewise model was found
and further used for the control effort described in C hapter 4.
Upon running th e statistical tests it was found th a t the d a ta w ithin the lx
and 2 x models were statistically similar and, therefore, we were able to create average
models, or ‘M aster Mice’, for the lx and 2x best fits of each model presented in
Chapter 2. Confidence and prediction intervals were then found for each ‘M aster
Mouse’ for each model. These plots are now theoretically able to be used in real time
in order to see adverse reactions and other possible issues during the experiment.
Several different control strategies were analyzed in C hapters 4 and 5. Initially,
in Chapter 4 a tracking LQR controller with a DDE is used assuming the same
initial injection as is used experimentally. Then, in C hapter 5 this same controller
is used with different initial injections for the purpose of limiting the overall am ount
of nanoparticles required for the entire experiment.

Then, the use of Dirac delta

functions as a control strategy was analyzed to observe if a discrete num ber of
injections would be at least as effective as the continuous injection in th e LQR
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controller. Finally, as it is a more commonly used controller in the engineering or
industrial settings, a tracking PID controller was used on the DDE. Each strategy
was found to be efficient and proficient a t tracking to a desired target (in this case,
tracking to a desired absorbtion). The to tal am ount of required nanoparticles (in /iL)
was found along with the error for each model and these values are given in Tables
5.1 and 5.4, respectively. Each strategy required a different am ount of nanoparticles
to reach th e desired target. However, as the error and oscillation of th e different
solutions also varied, it is not entirely clear which strategy is the most efficient for
experimental use.
While each m ethod was shown to be effective, the Dirac delta functions ap
peared to be the m ost efficient as it yielded low error with minimal to tal injection
and short run time. This control m ethod was also able to keep th e absorbance value
very close to the target for the m ajority of the length of the experiment.

6.2 D iscu ssio n an d F u tu re W ork
Each control effort, with the possible exception of the PID control, applied to
the exponential decay model shown runs within the tim e frame for which it could be
used in an experimental setting. Currently, the confidence and prediction intervals
described in Chapter 3 are in the beginning stage of being implemented for use in real
time during the run of the experiments. W ith the models being created in real time
it would be possible to see adverse reactions as they are happening and thus b etter
treat the patient. Once this is accomplished, it is th e goal to implement a control
strategy in an experimental setting as well. Each controller shows a different m ethod
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with different results to consider so the choice of control strategies to implement will
most likely depend on the specific needs of the individual patient.
These models only show a single biological com partm ent (th a t is, they model
the entire body at one tim e). Ideally, several different com partm ents will be added,
such as the tum or, reticulo endothelial system, and bloodstream (similar to the
models discussed in [IT]).

C urrently the experim ental data does not provide the

necessary information to show a m ulti-com partm ent model. T he addition of these
com partm ents will provide much b etter insight into where th e nanoparticles are
actually accumulating once they enter the body.

T he additional models will also

provide more opportunities for control design strategies to be applied. It would be of
specific interest to minimize the nanoparticle elim ination by the reticulo endothelial
system and to maximize the nanoparticle uptake in the tum or. Ideally, these m ethods
can also be used with other treatm ent strategies th a n the nanoparticle dosages if
enough data were provided for those methods.
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